Menu
Book A call

ABOUT US

IT’S TIME TO HEAL

Numinus exists to help the world heal, starting with addressing the global crisis in mental health by harnessing the power and promise of psychedelic medicine. Through our integrated model, we are actively contributing to the body of primary and clinical psychedelic research while delivering best-in-class therapeutic protocols across our clinics.

Going beyond breakthroughs

We understand that psychedelics are powerful medicines, but not magic pills. We understand that they can profoundly change lives, families, and communities, and that success requires more than just a breakthrough experience—it also takes careful, sensitive attention to every individual’s story, mindful preparation, and a grounded, realistic plan for what comes after.

Multidisciplinary expertise with human-centred care

Numinus boasts a diverse and interdisciplinary team of professionals, from physicians and psychiatrists to mindfulness teachers, nurses and psychotherapists, researchers and technicians. Our protocols are backed by rigorous science, and delivered by a team that understands that even the best tools still require genuine human care to be effective.

Curiosity and humility

At the core of what we do at Numinus is a deep sense of curiosity and humility about everything we encounter. We know that psychedelics, mindfulness, and embodied practices are not new tools, but rather owe a debt to some very old ways of being and caring for one another. We’re working every day to honour that wisdom and those traditions, and integrating it with the best that modern science has to offer.

OUR CLINICal TEAM

View All Members

RECENT COMPANY UPDATES

News
MDMA-Assisted Therapy for PTSD: In conversation with Rick Doblin & Payton Nyquvest
Why is real world evidence important for psychedelic research and how do therapy and psychedelics work together? MAPS founder, Rick Doblin, and our CEO, Payton Nyquvest share their thoughts, our […]
July 16, 2021
News
Numinus Announces Health Canada Approval of MAPS-Sponsored Open Label Study for MDMA-Assisted Therapy for PTSD
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disorders and will provide data on a regulated model for MDMA-assisted therapy VANCOUVER (July 12, 2021) – Numinus […]
July 12, 2021
News
Numinus Wellness To Acquire Neurology Centre of Toronto, Plans to Create Centre for Psychedelic Neurology
NCT’s treatment of neurological disorders combined with Numinus’ leadership in psychedelic-assisted therapy will offer opportunity to treat a range of chronic neurological conditions and common concurrent mental health challenges VANCOUVER […]
July 6, 2021
Questions?
Call us toll-free 1-833-NUMINUS (686-4687)
crosschevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram